BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 31 Jul 2017 Status changed from planning to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
- 24 Jul 2017 According to a Biohaven Pharmaceutical Holding Company media release, patients in this and another phase 3 study (700286075) will be eligible to participate in a long-term safety study.
- 24 Jul 2017 According to a Biohaven Pharmaceuticals media release, enrollment is expected to start in summer of 2017.